Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 117 of the 118 references it cites were found in a registry or an index.

Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management

Open access

Abstract

Recombinant preparations of the cytokine interferon (IFN)-alpha are increasingly used to treat a number of medical conditions, including chronic viral hepatitis and several malignancies. Although frequently effective, IFN alpha induces a variety of neuropsychiatric adverse effects, including an acute confusional state that develops rapidly after initiation of high-dose IFN alpha, a depressive syndrome that develops more slowly over weeks to months of treatment, and manic conditions most often characterised by extreme irritability and agitation, but also occasionally by euphoria. Acute IFN alpha-induced confusional states are typically characterised by disorientation, lethargy, somnolence, psychomotor retardation, difficulties with speaking and writing, parkinsonism and psychotic symptoms. Strategies for managing delirium should be employed, including treatment of contributing medical conditions, use of either typical or atypical antipsychotic agents and avoidance of medications likely to worsen mental status. Significant depressive symptoms occur in 21-58% of patients receiving IFN alpha, with symptoms typically manifesting over the first several months of treatment. The most replicated risk factor for developing depression is the presence of mood and anxiety symptoms prior to treatment. Other potential, but less frequently replicated, risk factors include a past history of major depression, being female and increasing IFN alpha dosage and treatment duration. The available data support two approaches to the pharmacological management of IFN alpha-induced depression: antidepressant pretreatment or symptomatic treatment once IFN alpha has been initiated. Pretreatment might be best reserved for patients already receiving antidepressants or for patients who endorse depression or anxiety symptoms of mild or greater severity prior to therapy. Several recent studies demonstrate that antidepressants effectively treat IFN alpha-induced depression once it has developed, allowing the vast majority of subjects to complete treatment successfully. Recent data suggest that IFN alpha-induced depression may be composed of two overlapping syndromes: a depression-specific syndrome characterised by mood, anxiety and cognitive complaints, and a neurovegetative syndrome characterised by fatigue, anorexia, pain and psychomotor slowing. Depression-specific symptoms are highly responsive to serotonergic antidepressants, whereas neurovegetative symptoms are significantly less responsive to these agents. These symptoms may be more effectively treated by agents that modulate catecholaminergic functioning, such as combined serotonin-noradrenaline (norepinephrine) antidepressants, bupropion, psychostimulants or modafinil. Additional factors to consider in selecting an antidepressant include potential drug-drug interactions and adverse effect profile. Finally, IFN alpha appears capable of inducing manic symptoms. Mania, especially when severe, is a clinical emergency. When this occurs, IFN alpha and antidepressants should be stopped, an emergency psychiatric consultation should be obtained, and treatment with a mood stabilizer should be initiated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2165/00023210-200519020-00002

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 118 references

Research works printed but not linked: 10

  1. Mattson, 1983, Cancer Treat Rep, 67, 958
  2. Wichers, 2004, J Psychiatry Neurosci, 29, 11
  3. Mizoi, 1997, Rinsho Shinkeigaku, 37, 54
  4. Lindsay, 1996, Hepatology, 24, 1034
  5. Lang, 2002, Ann Med Interne (Paris), 153, 22
  6. Owens, 1991, Pharmacol Rev, 43, 425
  7. Levenson, 1993, Am J Gastroenterol, 88, 760
  8. Yoshida, 2003, J Neuropsychiatry Clin Neurosci, 15, 242, 10.1176/jnp.15.2.242 · doi:10.1176/jnp.15.2.242
  9. Goodnick, 1996, Am J Psychiatry, 153, 294
  10. Goodnick, 1990, Am J Psychiatry, 147, 1091

Cited by

See all 536

Metadata

Authors
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H.
Affiliations
Emory University (US)
Corresponding author
Raison, Charles L
Venue
CNS Drugs
Published
2005
Volume
19
Issue
2
Pages
105-123
ISSN
1172-7047 (ISSN-L)
OpenAlex
W1986730863
Cited by
483
References
118
Citations by year
2026: 3 · 2025: 8 · 2024: 14 · 2023: 10 · 2022: 9 · 2021: 20 · 2020: 21 · 2019: 21 · 2018: 24 · 2017: 17 · 2016: 31 · 2015: 30 · 2014: 26 · 2013: 24 · 2012: 34
FWCI
1.81
Type
journal article
Language
en
Open access
Locations
  • CNS Drugs (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Mental Health (K23MH064619, MH 60723, MH069124, MH 64619, R01MH060723, K05MH069124)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
interferon-alpha, neuropsychiatric adverse effects, interferon-induced depression, antidepressant selection, serotonergic antidepressants, bupropion, modafinil, psychostimulants, manic symptoms, chronic viral hepatitis, cancer therapy
MeSH terms
Antiviral Agents, Behavioral Symptoms, Humans, Neoplasms, Psychiatric Status Rating Scales, Risk Factors, Prevalence, Interferon-alpha, Hepatitis C, Chronic, Mood Disorders, Recognition, Psychology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management. https://app.cochat.ai/papers/10.2165/00023210-200519020-00002
The paper
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005). Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management. CNS Drugs. https://doi.org/10.2165/00023210-200519020-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.